On November 23, 2020 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, reported it will conduct a conference call with investors to review financial results for its third quarter ended September 30, 2020, and provide an update on clinical and corporate developments, including its advanced stage drug candidates Piclidenoson and Namodenoson (Press release, Can-Fite BioPharma, NOV 23, 2020, View Source [SID1234571555]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Call Information

A press release reviewing the third quarter results and clinical updates will be issued prior to the call. A replay of the webcast will be archived on Can-Fite’s website for a period of time.